Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q1 2026 earnings

Reported April 8, 2026 · Before market open

Revenue$6.3MMiss by $8.0M
EPS-$0.79Miss by $0.03
Revenue estimate$14.3M
EPS estimate-$0.76

Next report

Oct 8, 2026 (in 2 months)
Revenue estimate$19.2M
EPS estimate-$0.65

Financials

Q1 2026

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation & ratios

Valuation

as of 02/28/26
See full
Market cap$1.64B+40.1%
Enterprise value$1.63B+45.1%
P/S22.9×+2.1×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio6×-0.3×

FAQ

When did Nurix Therapeutics, Inc. report Q1 2026 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q1 2026 earnings on April 8, 2026 before market open.
What were Nurix Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $6.3M and eps of $-0.79 for Q1 2026.
Did Nurix Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $14.3M by $8.0M. EPS missed the consensus estimate of $-0.76 by $0.03.
How did Nurix Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 66.1% from $18.5M a year earlier and eps declined 17.9% from $-0.67.
Where can I find Nurix Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001549595-26-000024) and the 10-Q periodic report (0001549595-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.